of pericarditis. A clinical study in patients with AML and high-risk MDS reported three responses in AML patients with Belinostat PXD101 two CR, despite a further test on a less intense, the SD were treated in four of 19 patients showed. Entinostat not refractory given promising results in 12 patients with AML without CR or PR, but only a reduction in the number of breath. The study showed that the drug can not be tolerated on a t Adjusted basis. After all, Romidepsin was at a dose of 13 mg once a week m2 tested in a cycle of 4 weeks in a clinical study in patients with chromosomal anomalies and divided the patients without these abnormalities. Romidepsin showed activity against leukemia t mie k in the cohort of patients with chromosomal anomalies can recruit HDACs: T, and INV16.
HDACIs in the treatment of multiple myeloma, multiple clinical studies support the safety and efficacy of certain HDACIs used as a single agent in the treatment of multiple myeloma have been studied. The first study was conducted with vorinostat was almost aborted by decision of the Sponsor and the maximum tolerable MLN8237 Possible dose has not even been found. Modest results were observed with panobinostat at a dose of 20 mg three times per week, and the v Llige lack of response in patients treated with Romidepsin reported w During the clinical response in a clinical trial in 4 of 14 patients reported Givinostat An association study Romidepsin in combination with bortezomib in patients with heavily pretreated myeloma good reps possibility demonstrated in 22 patients with four CR, VGPR PR two and six.
The study has not been completed, and a study of the combination of bortezomib in combination with panobinostat is evaluated. The side effect profile of HDACI The main purpose of these drugs is, epigenetic epigenetic HDAC in cancer database, the t to a better result with potentially minimal toxicity Goal leads. The HDACI are currently being tested in clinical trials have shown that s be R, although side effects have sometimes been reported seriously. The h Th most common toxicity Were associated with symptom My gastrointestinal or constitutional, h Dermatological abnormalities or changes St go t And were generally mild to moderate. A dose-escalation study of vorinostat in 41 AML patients was reported. Grade 3 4 adverse events were mainly fatigue, diarrhea and thrombocytopenia.
One of the first clinical trials with intravenous Sen panobinostat in patients with AML, ALL, MDS for asymptomatic Verl Ngerungen grade 3 Fredericia specified correction factor, further testing was conducted in the drug exposed to lymphoma patients reported hyperglycemia mie, Fatigue, diarrhea and Thrombozyth mie. Romidepsin showed Kardiotoxizit t that an electrocardiogram and embroidered ejection fraction of the patients the drug ben tion, And sorgf insurance valid selection of patients au He have significant cardi